Chemotherapy in Head and Neck Cancer Clinical Predictors of Tolerance and Outcomes

被引:11
|
作者
Kubicek, Gregory J. [1 ]
Kimler, Bruce F. [2 ]
Wang, Fen [2 ]
Reddy, Eashwer K. [2 ]
Girod, Douglas A. [3 ]
Williamson, Steven K. [4 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Radiat Oncol, Pittsburgh, PA USA
[2] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA
[3] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA
[4] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
关键词
head and neck cancer; chemotherapy; capsulation; tolerance; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; RANDOMIZED TRIAL; RADIOTHERAPY; CISPLATIN; CHEMORADIOTHERAPY; CARBOPLATIN; TIME;
D O I
10.1097/COC.0b013e3181e9c0a2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The addition of chemotherapy is more efficacious than radiation alone in the treatment of head and neck cancer (HNC). However, little data are available regarding the best chemotherapy agent and dosing, or factors associated with chemotherapy compliance. Methods: Retrospective review of all HNC patients receiving combined chemotherapy and radiotherapy at the University of Kansas Medical Center between 1994 and 2006. A total of 172 patients were analyzed in this report. Results: A total of 37% of patients were able to complete the entire chemotherapy regimen as intended. Multiple factors were examined in relation to chemotherapy completion and clinical outcome. Factors associated with not being able to complete chemotherapy on Cox regression analysis include use of a platinum agent and older age at diagnosis. No chemotherapy-related variables were prognostic for overall survival or disease-free survival. Conclusion: Factors associated with reduced chemotherapy compliance include older age and cisplatin agent. None of the chemotherapy characteristics (agent, total dose, and schedule) were associated with outcome.
引用
收藏
页码:380 / 384
页数:5
相关论文
共 50 条
  • [21] Clinical outcomes of photodynamic therapy for head-and-neck cancer
    Lou, PJ
    Jones, L
    Hopper, C
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2003, 2 (04) : 311 - 317
  • [22] Tomotherapy for head and neck cancer: clinical outcomes and patterns of failure
    Bolle, S.
    Thomas, F. Rothe
    Malika, A.
    Zefkili, S.
    Calugaru, V.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (10) : 697 - 697
  • [23] CHEMOTHERAPY FOR HEAD-AND-NECK CANCER
    PRICE, LA
    HILL, BT
    LANCET, 1982, 2 (8306): : 1045 - 1046
  • [24] Trends in, and predictors of, swallowing and social eating outcomes in head and neck cancer survivors: A longitudinal analysis of head and neck 5000
    Patterson, Joanne M.
    Lu, Liya
    Harding, Laura-Jayne Watsonc Sam
    Harding, Sam
    Ness, Andy R.
    Thomas, Steve
    Waylen, Andrea
    Waterboer, Tim
    Sharp, Linda
    ORAL ONCOLOGY, 2021, 118
  • [25] ADJUVANT CHEMOTHERAPY FOR HEAD AND NECK CANCER
    POMEROY, TC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1976, : 30 - 30
  • [26] Induction chemotherapy in head and neck cancer
    Hitt, R.
    ANNALS OF ONCOLOGY, 2006, 17 : X42 - X44
  • [27] Adjuvant chemotherapy in head and neck cancer
    Agarwala, SS
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (04) : 743 - +
  • [28] Induction chemotherapy in head and neck cancer
    Adelstein, DJ
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (04) : 689 - +
  • [29] Head and neck cancer - Guidelines for chemotherapy
    Catimel, G
    DRUGS, 1996, 51 (01) : 73 - 88
  • [30] Head and neck cancer: metronomic chemotherapy
    Francesca De Felice
    Daniela Musio
    Vincenzo Tombolini
    BMC Cancer, 15